Milan, Italy, and Morristown, NJ, USA – May 28, 2026, 3:30 pm CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the
Ad hoc announcement pursuant to Art. 53 LR
Newron reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study
Pause of enrollment limited to US
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, and Morristown, NJ, USA – March 24, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5
Presentations explore the role of glutamatergic modulation in treatment-resistant schizophrenia (TRS) across preclinical and clinical research
Milan, Italy, and Morristown
Ad hoc announcement pursuant to Art. 53 LR
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance
George Garibaldi and Paolo Zocchi proposed as new independent, non-executive Board members
Patrick Langlois and Luca Benatti to step down after long-standing service
Full Annual
Ad hoc announcement pursuant to Art. 53 LR
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of
Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant
Milan, Italy, and Morristown, NJ, USA, January 7, 2026 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
